Suneva Medical Inc has reached a milestone of distributing more than 1 million syringes of Bellafill at the close of 2021, the company announces.
Bellafill, which has been available for regenerative aesthetic use since 2007, is Suneva’s 5-year, FDA-approved filler for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on people’s cheeks.
In a 14-year post-market surveillance study, data suggests Bellafill had a consistently low adverse event rate (0.11%) comparable to other injectable hyaluronic acid (HA) fillers.
“The distribution of Bellafill’s millionth syringe is an extraordinary milestone for believers like myself at Suneva, but what’s more important to us is the improvement in self-image for the countless patients who have benefited from this product. Bellafill’s popularity has grown in recent years, as there are a growing number of patients who are looking for longer-term replacements to shorter-acting fillers, which typically last roughly one to two years. Bellafill can address this growing patient demand and energize the treatment-related needle and budget fatigue many aesthetic patients are likely to feel.”
— Pat Altavilla, Chief Executive Officer of Suneva
Bellafill is formulated to stimulate the patient’s own natural collagen, providing immediate correction and lasting up to 5 years with each treatment.
On January 12, 2022, Suneva Medical and Viveon Health Acquisition Corp announced that they entered into a definitive merger agreement. Upon completion of the transaction, the combined company’s securities are expected to be traded on the NYSE American under the symbol “RNEW.”
[Source(s): Suneva Medical Inc, PR Newswire]
